To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Cipralisant (GT-2331, tentative trade name Perceptin) is an extremely potent Histamine H3 receptor ligand originally developed by Gliatech. Cipralisant seemed to be well tolerated during early testing and it entered Phase II for ADHD in 2000. The relatively recent cloning of human H3 receptor, as well as the discovery of its constitutive activity provided the ability to better assess the activity of H3 receptor ligands. Unfortunately, cipralisant was reassessed as an H3 receptor agonist in human and rat recombinant systems.
Additional recommended knowledge
Gliatech filed for bankruptcy in 2002, and its intellectual property inherited by Merck. The development of cipralisant seems to have been suspended since 2003.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cipralisant". A list of authors is available in Wikipedia.|